ARKG ARK Genomic Revolution ETF
CBOEETFAs of 2026-07-10 16:00
Why ARKG matters now
ARK Genomic Revolution ETF (ARKG) is a US etf in Financial Services. The latest InvestLog snapshot shows $41.32 with -3.91% on the session and $1.26B in assets/market value.
The latest indexable market news headline is "Best ETF Areas of June" from Zacks Investment Research.
ETF Profile
Updated 2026-07-10Net Assets
$1.31B
NAV
$43.01
Expense Ratio
0.75%
Holdings
10
Issuer
ARK
Asset Class
Equity
Avg Volume
3,177,144
Inception
2014-10-30
Sector Exposure
Top Holdings
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| TEM | TEMPUS AI INC-CL A | 7.96% | $136.8M |
| TXG | 10X GENOMICS INC-CLASS A | 7.72% | $132.7M |
| TWST | TWIST BIOSCIENCE CORP | 7.39% | $127.0M |
| CRSP | CRISPR THERAPEUTICS AG | 6.65% | $114.3M |
| ABSI | ABSCI CORP | 6.59% | $113.2M |
| PSNL | PERSONALIS INC | 6.42% | $110.4M |
| BEAM | BEAM THERAPEUTICS INC | 4.45% | $76.4M |
| GH | GUARDANT HEALTH INC | 4.33% | $74.4M |
| LLY | ELI LILLY & CO | 4.29% | $73.6M |
| ILMN | ILLUMINA INC | 4.04% | $69.4M |
Latest News
Fund Info
Asset Type
ETF
Exchange
CBOE
Currency
USD
Issuer
ARK
Asset Class
Equity
NAV Currency
USD
The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.